StockData
CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Cellectis S.A.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 20, 2026
$0.93−0.11 (-11.01%)

Close on Oct 19, 2026

Market cap
$93.15M
P/E (TTM)
–
Dividend yield
–

Cellectis S.A. revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

Cellectis does not break out revenue by segment, region or product in the tagged data of its filings for this period type.